Daewoong Pharmaceutical to Launch Type 2 Diabetes New Drug 'Enblojeong' Domestically Next Month

The Nation's First Developed SGLT-2 Inhibitor Class Treatment
Targeting 100 Billion KRW in Sales Within 3 Years

Daewoong Pharmaceutical's self-developed type 2 diabetes treatment 'Enblo Tablets' will be launched domestically on the 1st of next month.

Enblojeong logo. [Image provided by Daewoong Pharmaceutical]

Daewoong Pharmaceutical announced on the 28th that, according to the Ministry of Health and Welfare's notification on the 25th, its self-developed new drug Enblo Tablets 0.3mg (active ingredient: Inavogliflozin) has been listed in the drug reimbursement list as a diabetes medication. The indications include ▲monotherapy ▲combination therapy with metformin ▲combination therapy with metformin and gemigliptin, totaling three cases. The launch date is May 1.

Daewoong Pharmaceutical's Enblo Tablets belong to the sodium-glucose co-transporter 2 (SGLT-2) inhibitor class and have demonstrated equivalent efficacy with only 0.3 mg, which is less than one-thirtieth of existing drugs in the same class, proving blood sugar-lowering effects and safety. Additionally, it boasts strengths such as ▲approximately 1% reduction in glycated hemoglobin compared to placebo ▲about 70% high target blood sugar achievement rate ▲improvement in cardiovascular risk factors (weight, blood pressure, lipids) ▲and abundant clinical data on Koreans.

Daewoong Pharmaceutical emphasized that Enblo Tablets are significant as a new drug developed in a short period through public-private cooperation under the expedited review system led by the Ministry of Food and Drug Safety. Enblo Tablets were designated as the first drug for the Ministry of Food and Drug Safety's expedited review (fast track) in 2020 and utilized the concurrent review system to accelerate the approval process.

Lee Chang-jae, CEO of Daewoong Pharmaceutical, stated, "Based on our leading research and development (R&D) capabilities in the pharmaceutical industry and accumulated sales and marketing power in the endocrinology field, we will quickly establish Enblo Tablets in the market. As the first domestically developed SGLT-2 inhibitor class diabetes treatment using purely Korean technology, we take pride as a leading domestic new drug company and will grow it into the top new drug in the diabetes treatment class through Daewoong Pharmaceutical's differentiated verified four-step strategy and sales operating principles."

Daewoong Pharmaceutical plans to make every effort to strengthen its position in domestic and international markets based on the efficacy and safety of Enblo Tablets. In line with the government's third comprehensive five-year plan for fostering and supporting the pharmaceutical and bio industry announced in March and the goal of becoming one of the top six global pharmaceutical and bio powers by 2027, the company aims to develop the domestic diabetes new drug into a global blockbuster.

According to global market research firm IQVIA, the SGLT-2 inhibitor class diabetes treatments formed a global market size of approximately 27 trillion KRW and a domestic market size of about 150 billion KRW as of 2021.

This content was produced with the assistance of AI translation services.